ClinicalTrials.gg
TerminatedNCT03487198Updated Dec 29, 2020

The Safety and Efficacy of Brexpiprazole as Adjunctive Therapy in the Treatment of Major Depressive Disorder

A Phase 3 interventional study of Brexpiprazole and Placebo in Major Depressive Disorder, sponsored by Otsuka Beijing Research Institute. Terminated at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-12-29.

Sponsored by Otsuka Beijing Research Institute (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Why this study was terminated
In consideration of the progress now and the expected enrollment in the next few years,the NDA will not be acquired before the patent went out.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
65
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 24 studies testing brexpiprazole in Depressive Disorder, Major — 1 open to participants now, 1 under way, none of them phase 3. brexpiprazole · Depressive Disorder, Major.

Enrollment
15th of 24
65 · median 189
Started
2018
with 3 others
Phase 3
16 of 24
none open now
Registered
17th of 24
by date
Lead sponsor
1 of 24
Otsuka Beijing Research Institute

Among the 24 studies testing brexpiprazole in Depressive Disorder, Major, this one is the 15th largest by enrollment, is one of 4 that started in 2018, is one of 16 in phase 3, and was the 17th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

1 of the 24 studies testing brexpiprazole in Depressive Disorder, Major is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About brexpiprazole

brexpiprazole: first FDA approval 2015 (REXULTI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 413 Depressive Disorder, Major studies recruiting now, 93 (23%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing brexpiprazole in Depressive Disorder, Major, or all of them as a file.
02

Study summary

This study is a multicenter, randomized, double-blind, placebo-controlled trial designed to assess the efficacy and safety of brexpiprazole as adjunctive therapy in the treatment of Major Depressive Disorder. A total of approximately 1100 subjects will be enrolled into the single-blind treatment for 6 weeks, and 480 incomplete responders will be randomized to brexpiprazole (2\~3 mg) or placebo in a 1:1 ratio (approximately 240 subjects in each group), for treatment of 6 weeks.

Read the detailed description

Screening phase: It can last up to 28 days and will begin when informed consent is signed. The screening phase will serve the following purposes: 1) To review the inclusion and exclusion criteria; 2) To allow for appropriate washout of prohibited medications; 3) To establish a pretreatment baseline of critical outcome measures.

Single-blind Prospective Treatment Phase (Phase A): It lasts 8 weeks; the purpose of the Phase A is to select the MDD subjects with incomplete response to ADT.

Randomized Double-blind Treatment Phase (Phase B): It lasts 6 weeks; the purpose of Phase B is to compare the efficacy and safety of Brexpiprazole as adjunctive therapy in the treatment of MDD patients with incomplete response to ADT.

Continued Treatment Phase after Phase A (Phase A+): It lasts 6 weeks; the purpose of Phase A+ is to continue treatment for subjects with complete response to ADT and not satisfying the criteria for Phase B.

Follow-up Phase: It lasts 4 weeks and only applies to the subjects from Phase B; the purpose of Follow-up Phase is to collect the safety information after the last dose of IMP.

03

Conditions studied

  • Major Depressive Disorder

Keywords

  • Major Depressive Disorder
  • Brexpiprazole
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The subject who are able to provide signed written .
  2. Male and female outpatients 18 to 65 years of age, inclusive, at the time of signing the informed consent.
  3. Subjects with both a diagnosis of MDD, and in a current Major Depressive Episode, according to the diagnostic criteria in and confirmed by the Mini International Neuropsychiatric Interview (MINI). The current Major Depressive Episode must be ≥ 8 weeks in duration.
  4. Subjects must have reported a history for the current Major Depressive Episode of an inadequate response to at least one and no more than three standard antidepressant treatments (including any antidepressants being received during Screening period, if the antidepressants treatment meets criteria of standard treatment). For the most recent antidepressant treatment, the subject must not report ≥ 50% improvement.

    Standard treatment is defined as: an antidepressant treatment for at least 6 weeks in duration (at least 3 weeks if combined treatment) at a minimum effective dose (or higher) according to prescription drug labels. At least once of 1 to 3 standard treatments is monotherapy for more than 6 weeks.

    An inadequate response is defined as: \< 50% reduction in depressive symptom severity, as measured by the subject's self-report score on Visual Analogue Scale (VAS).

  5. Subjects with a HAM-D17 Total Score ≥ 18 at the Screening and Baseline visits.

Phase B (Double-blind Randomization Phase)

At the end of Phase A (Week 8 visit), the subjects entering Phase B should also meet all of the following inclusion criteria (criteria for incomplete response):

  1. HAM-D17 total score ≥14 at the end of phase A.
  2. \< 50% reduction in HAM-D17 total score at the end of phase A (end of Week 8) relative to baseline.
  3. A CGI-I score ≥ 3 at Weeks 2, 4, 6, and 8.

Exclusion criteria

Exclusion Criteria:

  1. Females of and male subjects who are not willing to or cannot practice methods during the trial and for 30 days after the last dose.
  2. Females who are breast-feeding or lactating and who have a positive pregnancy test result (Urine or serum test) prior to screening or randomization (within 72 hours).
  3. Subjects who report treatment with adjunctive antipsychotic medication with an antidepressant during the current Major Depressive Episode.
  4. Subjects who report allergies or an intolerability to all protocol-specified ADTs or subjects with for protocol-specified ADTs described in their prescription drug labels.
  5. Subjects who have had an ECT treatment history at any time in the past or at present, or who have had a vagus nerve stimulation or deep brain stimulation device implanted for management of treatment-resistant depression.
  6. Subjects with a current need for hospitalization or who have been hospitalized within four weeks prior to screening for the current Major Depressive Episode.
  7. Subjects with a current Axis I () diagnosis of:

    • Delirium, dementia, amnestic or other cognitive disorder
    • Schizophrenia, schizoaffective disorder, or other psychotic disorder
    • Bipolar I or II disorder
    • Eating disorder (including anorexia nervosa or bulimia)
    • Obsessive compulsive disorder
    • Panic disorder
    • Post-traumatic stress disorder
  8. Subjects with a current Axis II (DSM-IV-TR) diagnosis of borderline, antisocial, paranoid, schizoid, schizotypal or histrionic personality disorder.
  9. Subjects experiencing hallucinations, delusions or any psychotic symptomatology in the current Major Depressive Episode.
  10. Subjects who have met DSM-IV-TR criteria for substance abuse or dependence within the past 180 days prior to screening; including alcohol and benzodiazepines, but excluding caffeine and nicotine.
  11. Subjects receiving new onset psychotherapy (individual, group, marriage, or family therapy) within 6 weeks of screening or at any time during participation in the trial.
  12. Subjects who present a serious risk of suicide.

    • Subjects who answer "Yes" on the C-SSRS Suicidal Ideation Item 4 and whose most recent episode meeting criteria for this C-SSRS Item 4 occurred within the last 6 months; OR
    • Subjects who answer "Yes" on the C-SSRS Suicidal Ideation Item 5 and whose most recent episode meeting criteria for this C-SSRS Item 5 occurred within the last 6 months; OR
    • Subjects who answer "Yes" on any of the 5 C-SSRS Suicidal Behavior Items (actual attempt, interrupted attempt, aborted attempt, preparatory acts or behaviors, or suicidal behavior) and whose most recent episode meeting criteria for any of these 5 C-SSRS Suicidal Behavior Items occurred within the last 2 years; OR
    • Subjects who, in the opinion of the investigator, present a serious risk of suicide.
  13. Medical history or clinical evidence (abnormal clinical significant laboratory test, vital signs, or findings, judged by investigator) shows the health condition of the subject may cause an undue adverse event or interfere with assessments of safety/efficacy during the course of the trial.
  14. Subjects with a history of ischemic heart disease or myocardial infarction, congestive heart failure (whether controlled or uncontrolled), angioplasty, stenting, or coronary artery bypass surgery.
  15. Subjects with insulin-dependent diabetes mellitus (IDDM, i.e., any subjects using insulin) and uncontrolled non-IDDM are excluded. Subjects with non-IDDM may be eligible for the trial if their condition is stable as determined by satisfying ALL of the following criteria:

    • Glycosylated () \< 7.0%, AND
    • Screening glucose must be ≤ 125 mg/dL or ≤ 6.94 mmol/L (fasting) or \<200 mg/dL or \<11.1 mmol/L (non-fasting). If the non-fasting screening glucose is ≥ 200 mg/dL or ≥ 11.1 mmol/L, subjects must be retested in a fasted state and the retest value must be ≤ 125 mg/dL or ≤ 6.94 mmol/L, AND
    • Subject has been maintained on a stable regimen of oral anti-diabetic medication(s) for at least 28 days prior to screening or diabetes has been well-controlled by diet for at least 28 days prior to screening, AND
    • Subject has not had any hospitalizations within the 12 months prior to screening due to diabetes or complications related to diabetes, AND
    • Subject's diabetes is not newly diagnosed during screening for the trial.
  16. Subjects with hypothyroidism or hyperthyroidism (unless condition has been stabilized with medications for at least the past 90 days) and/or an abnormal result for free T4 at screening. Eligibility of subjects excluded based on an abnormal free T4 result can be discussed with the medical monitor if, in the investigator's judgment, the subject is a suitable candidate for the trial.
  17. Subjects with a history of neuroleptic malignant syndrome (NMS) or 5-HT syndrome.
  18. Subjects with a history of true allergic response (i.e., not intolerance) to more than one class of medications.
  19. Subjects with epilepsy or a history of seizures, except for a single seizure episode, for instance childhood febrile seizure, post traumatic, or alcohol withdrawal.
  20. Subjects with uncontrolled hypertension (diastolic blood pressure [DBP] > 95 mmHg in any position) or symptomatic hypotension, or orthostatic hypotension which is defined as a decrease of ≥ 30 mmHg in systolic blood pressure (SBP) and/or a decrease of ≥ 20 mmHg in DBP after at least 3 minutes standing compared to the previous supine blood pressure, OR development of symptoms.
  21. The following laboratory test and ECG results are exclusionary:

    • ≥ 450 msec (for males) or ≥ 470 msec (for females) in ECG
    • ≤75×109/L (7,5000/mm3)
    • Hemoglobin ≤90 g/L (9 g/dL)
    • Neutrophils ≤1×109/L (1,000/ mm3)
    • or ALT > 2 × (ULN)
    • Creatinine ≥ 2 mg/dL
    • Creatine phosphokinase (CPK) > 3 × ULN
    • HbA1c ≥ 7.0%
  22. Treatment with MAOI (e.g., Nardil® [phenelzine]) within the 2 weeks prior to the start of Phase A.
  23. Use of benzodiazepines and/or hypnotics (including non-benzodiazepine sleep aids) within 1 week prior to the start of Phase A, but excluding short-acting non-benzodiazepine sleep aids (ie, zolpidem, zaleplon, zopiclone, and eszopiclone only).
  24. Subjects who participated in a clinical trial within the past 90 days or who participated in more than two clinical trials within the past year.
  25. Any subject who, in the opinion of the investigator, should not participate in the trial. Such as, any subject who is impossible to compliance with the protocol, or who would be likely to require prohibited concomitant medication/therapy during the trial.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
65 participants (actual)

Study arms

  • Experimental
    Brexpiprazole

    2-3 mg/day, once daily for 6 weeks, oral administration

    Drug: Brexpiprazole

  • Placebo comparator
    Placebo

    2-3 mg/day, once daily for 6 weeks, oral administration

    Drug: Placebo

Interventions

  • Brexpiprazole 2-3mg/day

  • DrugPlacebo

    Placebo 2-3 mg/day

06

What researchers measure

Primary outcomes

  1. Change from the end of Phase A (Week 8 visit) to the end of Phase B (Week 14 visit) in the MADRS Total Score

    The objective of the primary analysis is to compare the efficacy of brexpiprazole (2\~3 mg/day) to placebo as adjunctive therapy to an assigned open-label ADT in adult subjects with MDD who demonstrate an incomplete response after 8 weeks of treatment with the same assigned open-label antidepressant therapy (ADT). The efficacy is assessed by the change from the end of Phase A (Week 8 visit) to the end of Phase B (Week 14 visit) in the MADRS Total Score

    Time frame: Week 8 and Week 14

Secondary outcomes

  1. Change from the end of Phase A (Week 8 visit) to the end of Phase B (Week 14 visit) in SDS Mean Score

    The efficacy is assessed by the change from the end of Phase A (Week 8 visit) to the end of Phase B (Week 14 visit) in SDS Mean Score

    Time frame: Week 8 and Week 14

  2. Change from the end of Phase A (Week 8 visit) in MADRS Total Score for every trial week visit in Phase B other than Week 14 visit

    The efficacy is assessed by the change from the end of Phase A (Week 8 visit) in MADRS Total Score for every trial week visit in Phase B other than Week 14 visit

    Time frame: Week 8 and Week 14

  3. Change from the end of Phase A (Week 8 visit) for every trial week visit in Phase B in CGI - Severity of Illness scale (CGI-S) score

    The efficacy is assessed by the Change from the end of Phase A (Week 8 visit) for every trial week visit in Phase B in CGI - Severity of Illness scale (CGI-S) score

    Time frame: Week 8 and Week 14

  4. Change from the end of Phase A (Week 8 visit) to the end of Phase B (Week 14 visit) in HAM-D17 Score

    The efficacy is assessed by the change from the end of Phase A (Week 8 visit) to the end of Phase B (Week 14 visit) in HAM-D17 Score

    Time frame: Week 8 and Week 14

  5. CGI - Improvement scale (CGI-I) score for every trial week visit in Phase B

    The efficacy is assessed by the CGI-I score for every trial week visit in Phase B

    Time frame: Week 8 and Week 14

  6. MADRS Response Rate at every trial week visit in Phase B

    The efficacy is assessed by the MADRS Response Rate at every trial week visit in Phase B, where response is defined as ≥ 50% reduction in MADRS Total Score from the end of Phase A (Week 8 visit)

    Time frame: Week 8 and Week 14

  7. CGI-I Response rate at every trial week visit in Phase B

    The efficacy is assessed by the CGI-I Response rate at every trial week visit in Phase B, where response is defined as a CGI-I score of 1 or 2 (very much improved or much improved)

    Time frame: Week 8 and Week 14

  8. Change from the end of Phase A (Week 8 visit) to the end of Phase B (Week 14 visit) in 16-item Quick Inventory of Depressive Symptomatology Self-Report (QIDS-SR16) Score

    The efficacy is assessed by the Change from the end of Phase A (Week 8 visit) to the end of Phase B (Week 14 visit) in QIDS-SR16 Score

    Time frame: Week 8 and Week 14

  9. QIDS-SR16 Response Rate at every trial week visit in Phase B

    The efficacy is assessed by the QIDS-SR16 Response Rate at every trial week visit in Phase B, where response is defined as ≥ 50% reduction in QIDS-SR16 Total Score from the end of Phase A (Week 8 visit)

    Time frame: Week 8 and Week 14

  10. QIDS-SR16 Complete Remission Rate (recovery) at every trial week visit in Phase B

    The efficacy is assessed by the QIDS-SR16 Complete Remission Rate (recovery) at every trial week visit in Phase B, where complete remission (recovery) is defined as QIDS-SR16 Total Score ≤ 5

    Time frame: Week 8 and Week 14

07

Study locations

1 site
  • Beijing Anding Hospital of Capital Medical University
    Beijing, Beijing 100088, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2018 to primary completion in May 2019, 12 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2018
First posted
Apr 3, 2018
StartActual
May 30, 2018
Primary completionActual
May 30, 2019
CompletionActual
May 30, 2019
Last update
Dec 29, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 29, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03487198
Responsible party
Sponsor
First posted
Apr 3, 2018
Start date
May 30, 2018
Primary completion
May 30, 2019
Completion
May 30, 2019
Last update
Dec 29, 2020

Study contacts

Patyman Juma
study director · Otsuka Beijing Research Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brexpiprazole

Start the discussion